أعرض في EDS

220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer

التفاصيل البيبلوغرافية
العنوان: 220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer
المؤلفون: M. Nechaeva, Assen Dudov, Martin Schuler, A. Rusyn, G. Manikhas, Florian Lordick, A. Pecheniy, Ugur Sahin, Igor Bondarenko, O. Tu¨ reci, Igor Bazin, E. Gotovkin, Bohuslav Melichar, Zanete Zvirbule, Ihor Vynnychenko, N. Fadeeva, Y. Vinnyk, Christoph Huber, S.-E. Al-Batran
المصدر: Annals of Oncology. 27:ix69
بيانات النشر: Elsevier BV, 2016.
سنة النشر: 2016
مصطلحات موضوعية: Oncology, medicine.medical_specialty, biology, business.industry, Cancer, Hematology, Gastroesophageal Junction, medicine.disease, Oxaliplatin, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, biology.protein, medicine, 030212 general & internal medicine, Antibody, Claudin, business, IMAB362, Epirubicin, medicine.drug
تدمد: 0923-7534
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d5da5cb37adefcc03255e9e61be295b
https://doi.org/10.1016/s0923-7534(21)00377-x
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....2d5da5cb37adefcc03255e9e61be295b
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09237534